have been implemented to ensure we continue, where possible, to deliver high quality clinical trials. Technology has provided many solutions to these challenges and trial managers have adapted to new ways of working whilst continuing to deliver their clinical trials. Trial management groups are now faced with new uncertainties around re-starting clinical trials and it is unclear currently how this will go, though working together with sponsors, funders and site teams is clearly a priority. Clinical trial teams have worked together to ensure their trials have adapted quickly whilst ensuring participant safety is given utmost importance. There are clear examples where the trial community have come together to share experiences and expertise and this should continue in the future to ensure the innovative practices developed become embedded in the design and conduct of clinical trials in the future.
UKTMN is funded by the Nuffield Department of Population Health (NDPH) at the University of Oxford.
We thank Graeme MacLennan, Director of the Centre for Health Care Randomised Trials (CHaRT) for the inspiration for this article and UKTMN members for their input into its content. We also thank the huge clinical trial community, both nationally and internationally, for continuing to run clinical trials in these challenging times, and for regulatory agencies to adapting their processes to enable efficiencies.
- clinical trial
- Trial management
- Clinical trial
- Data Accuracy
- Risk Assessment
- Risk Factors
- Data Collection
- Coronavirus Infections/diagnosis
- Host-Pathogen Interactions
- Clinical Trials Data Monitoring Committees
- Time Factors
- Patient Safety
- Clinical Trials as Topic/methods
- Research Design
- Pneumonia, Viral/diagnosis